Altasciences acquires Sinclair Research and continues to expand pre-clinical platform

Altasciences, an integrated contract research organisation/contract development and manufacturing organisation (CRO/CDMO) offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof-of-concept, announced today the completed acquisition of Sinclair Research, a pre-clinical CRO located in the US midwest. Complementing existing locations on the east and west coast, the new site will facilitate even greater access to Altasciences’ pre-clinical services across the U.S.

“This acquisition will add significant capacity and expertise to Altasciences’ existing pre-clinical offering,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “Sinclair’s experience conducting research on a wide variety of species in a comprehensive range of drug classes will broaden our current pre-clinical offering and support Altasciences’ focus on providing our clients with customised solutions.”

With over 80 animal rooms, Sinclair Research is a large non-clinical CRO in the US, providing full-service Investigational New Drug (IND) and New Drug Application (NDA)-enabling toxicology and safety pharmacology services. Built on more than 50 years of experience, Sinclair Research provides services to support biopharmaceutical, animal health and medical device development programmes.

“We are very excited to be joining the Altasciences team and look forward to being able to offer our pre-clinical services to a broader market by leveraging the resources and expertise of an integrated, global CRO,” stated Guy Bouchard, Chief Executive Officer at Sinclair Research. 

“With this acquisition, Altasciences is continuing to advance its strategic growth plan to provide an expanded range of services in support of our integrated early-phase drug development solutions. Sinclair Research shares our commitment to animal welfare and we look forward to merging our talents and working together with our new team of pre-clinical experts in the midwest,” added Chris Perkin, Altasciences’ Chief Executive Officer.